Document:

Exhibit 10.72

Exhibit 10.72

NUCRYST PHARMACEUTICALS CORP.

STOCK OPTION AWARD AGREEMENT

GRANT of Options made effective as of (the “Grant Date”)

	TO: 	 	(the “Participant”)
	 
	BY: 	 	NUCRYST Pharmaceuticals Corp. (the “Company”)

     WHEREAS, on December 21, 2005, the Board of Directors of the Company (the “Board”) approved
and adopted the Company’s 1998 Equity Incentive Plan (as amended) (the “Plan”) and the Plan was
subsequently approved by the Toronto Stock Exchange; and

     WHEREAS, by resolution of the Board made on                          , the Board
granted the Options provided for herein to the Participant in connection with the Participant’s
services to the Company, such grant to be effective the Grant Date and subject to the terms set
forth herein;

     NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties
hereto agree as follows:

	1.	 	Equity Incentive Plan

The grant by the Company to the Participant of Options by this Agreement is made pursuant to the
terms and conditions of the Plan. This Agreement and the terms and conditions of the grant of
Options are subject in all respects to the terms and conditions of the Plan, which is made a part
of this Agreement. The Participant, by acceptance of this Agreement, agrees to be bound by the
Plan (and any regulations that may be established under the Plan) and acknowledges receipt of a
copy of the Plan and this Agreement. Terms that are defined in the Plan and not otherwise defined
in this Agreement shall have the same meaning when used in this Agreement as in the Plan.

	2.	 	Grant of Options

The Company grants to the Participant, effective the date of this Agreement,                     
options (defined in the Plan and this Agreement as “Options” or individually as an
“Option”) to purchase Common Shares of the Company (which Common Shares, when purchased by the
exercise of Options, are defined as “Optioned Shares”), subject to the terms and conditions of this
Agreement and the Plan.

	3.	 	Option Price

The exercise price of each Option (which is defined in the Plan as the “Option Price”) is $.

	4.	 	Expiry Date

Unless earlier terminated in accordance with the terms of the Plan or this Agreement, the Options
shall terminate on, and may not be exercised in whole or in part after, 5:00 p.m. (Edmonton,
Alberta, Canada time) on                      (the “Expiry Date”); provide,
however, that where the Expiry Date of the Options occurs during a Blackout Period or within ten
Non Blackout Trading Days following the end of a Blackout Period, the Expiry Date shall be the date
which is ten Non-Blackout Trading Days following the end of such Blackout Period.

 

 

	5.	 	Vesting

Unless otherwise set forth in this Agreement, the Options shall vest and shall become exercisable:

	 	(a)	 	as to 1/3 shares on the first anniversary of the Grant Date until the
Expiry Date;

	 	(b)	 	as to 1/3 shares on the second anniversary of the Grant Date until
the Expiry Date; and

	 	(c)	 	as to 1/3 shares on the third anniversary of the Grant Date until the
Expiry Date.

	6.	 	Accelerated Vesting

Notwithstanding the vesting provisions contained in Section 5 above, in the event that a Change in
Control of the Company or an Elimination of the Public Float occurs prior to the Expiry Date, the
Options shall immediately become fully vested and exercisable as to all the Optioned Shares.

Whenever used in this Agreement, the following terms shall have the meanings set forth below:

	 	(a)	 	“Change in Control of the Company” means the occurrence of a transaction or
series of transactions, either alone or in combination with any other events or
transactions, as a result of which:

	 	(i)	 	Any Unrelated Person (other than the Participant or any of
the Participant’s Associates) acquires or becomes the beneficial owner of, or
a combination of Unrelated Persons (not including the Participant or any of
Participant’s Associates) acting jointly or in concert acquires or becomes the
beneficial owner of, directly or indirectly, more than 50% of the voting
securities of the Company, whether through the acquisition of previously
issued and outstanding voting securities, or of voting securities that have
not been previously issued, or any combination thereof, or any other
transaction having a similar effect, unless the acquisition of such voting
securities is approved by a majority of directors of the Company in office
immediately prior to such acquisition;

	 	(ii)	 	the shareholders of the Company approve: (1) any plan or
proposal for the liquidation or dissolution of the Company; or (2) the sale,
lease, exchange, disposition or other transfer of all or substantially all of
the assets of the Company;

	 	(iii)	 	50% or more of the issued and outstanding voting securities
of the Company become subject to a voting trust in which neither the
Participant nor any of Participant’s Associates nor Westaim participates;

	 	(iv)	 	a majority of the directors of the Company are removed from
office at any annual or special meeting of shareholders, or a majority of the
directors of the Company resign from office over a period of 60 days or less,
unless the vacancies created thereby are either (1) filled by appointments
made by the remaining members of the Board of Directors of the Company, or (2)
are filled by nominees proposed by the Board of Directors, or Westaim; or (3)
the Board of Directors of the Company determines not to fill the vacancies in
connection with a reduction in the size of the Board of Directors of the
Company approved by a majority of directors of the Company then in officer; or

 

 

	 	(v)	 	a consolidation, share exchange or merger of the Company
occurs: (1) in which the shareholders of the Company immediately prior to such
transaction do not own at more than 50% of the voting securities of the entity
which survives/results from that transaction; or (2) in which a shareholder of
the Company who does not own more than 50% of the voting securities of the
Company immediately prior to such transaction, owns more than 50% of the
Company’s voting securities immediately after such transaction.

	 	(vi)	 	“Elimination of Public Float” means the occurrence of a
transaction or series of transactions, either alone or in combination with any
other events, as a result of which: (1) Westaim acquires or becomes the
beneficial owner of, directly or indirectly, 100% of the publicly-traded
voting securities of the Company; or (2) the voting securities of the Company
cease to be publicly-traded on a stock exchange or in the over-the-counter
market.

	 	(b)	 	“Associate” has the meaning attributed to such term in the Business
Corporations Act (Alberta) as the same may be amended from time to time and any
successor legislation thereto.

	 	(c)	 	“Person” means any individual, partnership, limited partnership, joint
venture, syndicate, sole proprietorship, company or corporation with or without share
capital, unincorporated association, trust, trustee, executor, administrator or other
legal personal representative, regulatory body or agency, government or governmental
agency, authority or entity however designated or constituted.

	 	(d)	 	“Unrelated Person” shall mean and include any Person other than the Company,
Westaim, or any officer or director of the Company.

	 	(e)	 	“Westaim” shall mean The Westaim Corporation.

	7.	 	Termination

If the Participant’s employment with the Company (or any Subsidiary of the Company) is terminated
before the Expiry Date, then the vesting of all Options shall stop immediately upon the Termination
Date, and any Options that have vested as at the Termination Date shall remain in force and can be
exercised by the Participant in accordance with the following provisions:

	 	(a)	 	If the Termination Date shall occur for any reason whatsoever other than
death or Disability, then the Participant will have 30 days after the Termination Date
or until the Expiry Date (whichever is earlier) to exercise all or any portion of such
vested Options.
	 
	 	(b)	 	If the Termination Date shall occur by reason of death or Disability, then
the Participant (or his/her personal legal representative) may, within 180 days after
the Termination Date or before the Expiry Date (whichever is earlier) exercise all or
any portion of such vested Options.

At the end of the periods specified above or the Expiry Date, whichever is earlier, all of the
Options shall terminate and be of no further force or effect. “Termination Date” is defined in the
Plan, and in no event shall any period during which the Participant is in receipt of or entitled to
be in receipt of severance pay or pay in lieu of notice serve to extend the Termination Date.

	8.	 	Method of Exercise of Options and Payment

The Options shall be exercised (in accordance with the provisions of this Agreement and the Plan)
from time to time by giving notice in writing to the Company and setting forth the number of
Options being exercised. Such notice shall be accompanied by cash or certified cheque payable to
the Company, or any other form of payment satisfactory to the Company, in the full amount of the
purchase price for the Optioned Shares being purchased (such purchase price being equal to the
number of Options being exercised times the Option Price) plus payment of any applicable Federal,
State, Provincial or local taxes, or any other taxes which the Company may be obligated to collect
as a result of the issue or transfer of Optioned Shares upon such exercise of the Options. The
Participant shall provide the Company with any additional documents that the Company may require.
As soon as reasonably practicable after the proper
exercise of any Options, the Company shall issue to the Participant a share certificate
representing the Optioned Shares acquired.

 

 

	9.	 	General Matters

	 	(a)	 	Options are not transferable or assignable.
	 
	 	(b)	 	This Agreement is not an employment contract and nothing in this Agreement
shall be deemed to create in any way whatsoever any obligation on the Participant’s
part to continue to work for the Company (or any subsidiary of the Company), or of the
Company (or any subsidiary of the Company) to continue to employ the Participant.
	 
	 	(c)	 	The Participant acknowledges that the Company may be required to disclose to
the securities regulatory authorities, the Exchange or other regulatory authorities
duly authorized to make such request, the name, address and telephone number of the
Participant, the number of Options granted, and if required by applicable securities
legislation, regulations, rules, policies or orders or by any securities commission,
the Exchange or other regulatory authority, it will, in a timely manner, execute,
deliver, file and otherwise assist the company in filing, such reports, undertakings,
and other documents with respect to the Options as may be required or requested by the
Company to enable the Company to comply with applicable securities legislation,
regulations, rules, policies or orders or the requirements of any securities
commission or other regulatory authority or the Exchange.
	 
	 	(d)	 	This Agreement and the Plan constitute the entire agreement between the
parties relating to the grant of Options to the Participant and supersedes all prior
communications, representations and negotiations in respect thereto provided that, for
greater certainty, in the event of any inconsistencies as between this Agreement and
the Plan, such matters shall be governed by the terms and provisions of the Plan.
	 
	 	(e)	 	For the grant of the Options to be effective, this Agreement must be executed
by the Participant and returned to the Company.
	 
	 	(f)	 	This Agreement shall be governed by the laws of the Province of Alberta. The
parties agree that any disputes under this Agreement shall be resolved by the courts
of Alberta and each of the parties irrevocably attorn to the non-exclusive
jurisdiction thereof with respect to all such matters and the transactions
contemplated herein.
	 
	 	(g)	 	Time shall be of the essence of this Agreement.
	 
	 	(h)	 	The Participant acknowledges that neither the Plan or this Agreement
restricts the Company’s ability to conduct its business (including, but not limited
to, such decisions as transactions with related parties, new product development
efforts, cancellation of existing products, mergers and acquisitions, or corporate
dissolution) regardless of the effect those decisions may have on the value of
Options.
	 
	 	(i)	 	The Participant shall not have any of the rights and privileges of a
shareholder of the Company by virtue of being granted Options.

The Company and the Participant have executed this Agreement on the            day of
                               to be effective as of the Grant Date.

NUCRYST PHARMACEUTICALS CORP.

	 	 	 	 	 
	By:Exhibit 10.73

Exhibit 10.73

May 2009

NUCRYST Pharmaceuticals Corp.

Board Compensation

	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Category	 	 	NUCRYST Plan	 	 	Annual Value (approx.)
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Initial Equity Grant
	 	 	5,000 Restricted Shares	 	 	n/a (1)
	 
	 	 	(immediate vesting, with 1,000 available for sale in 	 	 	 
	 
	 	 	1 year and 4,000 to be held for duration of board service)	 	 	 
	 
	 	 	8,000 Stock Options	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Annual Retainer
	 	 	$15,000	 	 	$5,000
	(Paid quarterly excluding
	 	 	 	 	 	 
	Chairman of the Board)
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Board Meeting Fees
	 	 	$2,000/meeting	 	 	$12,000  (assumes 6 meetings/year)
	(including telephone meetings)
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Annual Stock Award
	 	 	3,000 Restricted Shares	 	 	$2,750(2)
	 
	 	 	(50% vest after 1 year and 50% after second year)	 	 	 

	 
	 	 	2,000 Stock Options	 	 	Total Annual Board Comp. - $29,750 [TBD – based 
	 
	 	 	 	 	 	on share price change]
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Chairman of the Board Retainer
	 	 	$100,000	 	 	$100,000
	(Paid quarterly and in lieu of
board and committee meeting
fees)
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Committee Chair Annual Retainer
	 	 	$7,500 for Audit	 	 	$7,500 Audit Chair
	(Paid quarterly)
	 	 	$5,000 for Governance, Nominating & Compensation	 	 	$5,000 Governance, Nominating and Compensation Chair
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Committee Meeting Fees
	 	 	Audit	 	 	Assumes 6 Audit Committee Meetings per year
	(including telephone meetings)
	 	 	     Chair – $1,500/meeting	 	 	Chair – $9,000
	 
	 	 	     Member – $1,200/meeting	 	 	Member – $7,200
	 
	 	 	Governance, Nominating and Compensation Committee	 	 	Assumes 4 Governance, Nominating and Compensation
	 
	 	 	     Chair – $1,000/meeting	 	 	Committee meetings per year for
	 
	 	 	     Member – $800/meeting	 	 	Chair – $4,000
	 
	 	 	 	 	 	Member – $3,200
	 
	 	 	 	 	 	 

	 
	 	 	 	 	 	Total Annual Committee Comp. – $19,700
	 
	 	 	 	 	 	 

	 
	 	 	 	 	 	Total Annual Compensation – $49,450
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Special Committee
	 	 	$15,000 Special Committee Chair  Retainer	 	 	Special Committee fees not included
with Annual Compensation as 
	 
	 	 	$10,000 Special Committee Member Retainer	 	 	they are one time fees paid to the Special
Committee Chair and 
	 
	 	 	$2,000/meeting for Chair & Member	 	 	members of the committee when a Special Committee is required.
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

 

	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Category	 	 	NUCRYST Plan	 	 	Annual Value (approx.)
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Travel Fees	 	 	$1,000.00 for travel involving airtime of greater than 4 hours one way in North America
	 	 	 	$2,000.00 for travel involving airtime of greater than 4 hours one way from another continent
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Additional Fees
	 	 	$2,000 per day plus	 	 	 
	(For additional board work performed 
	 	 	$1,000.00 for travel involving airtime of greater than 4 hours one way in North America
	at the request of the Board)
	 	 	$2,000.00 for travel involving airtime of greater than 4 hours one way from another continent
	 
	 	 	 	 	 	 
	 	 	 	 	 	 	 

	(1)	 	The initial equity grant is not included in annual compensation however has an approximate
value of $8,000.00 based on a share price of $0.55 as of May 13, 2009.

	(2)	 	Approximate value of equity is based on share price of $0.55 as of May 13, 2009, and values
restricted shares at face value and options at 0.333 of current share price.

Notes:

	(1)	 	Directors are required to hold minimum equity equal in value to 2.5 times the annual
retainer, which equates to $37,500. For purposes of this calculation, common and restricted shares are included, but options are not. Directors have 3 years to achieve this minimum
ownership level.

	(2)	 	The company has available to it a deferred share unit plan whereby directors may elect to
receive DSUs in lieu of cash fees (retainers and meeting fees). This form of compensation
will not likely be utilized for the 2009 calendar year.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]